Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4–1BB: A preclinical study in multiple myeloma
2024 · Biomedicine & Pharmacotherapy · 3 citations
https://doi.org/10.1016/j.biopha.2024.116877